Holds one active US DMF for gatifloxacin, filing since 2003. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for gatifloxacin, filing since 2007. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds one active US DMF for gatifloxacin, filing since 2010. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 30 markets.
Holds one active US DMF for gatifloxacin, filing since 2012. Its 2025 FDA inspection closed as VAI.
Holds one active US DMF for gatifloxacin, filing since 2003. Its 2025 FDA inspection closed as VAI.
Holds one active US DMF for gatifloxacin, filing since 2001. Its GMP is recognised in 3 markets.
Holds one active US DMF for gatifloxacin, filing since 2024.
Registered with SFDA (Saudi Arabia) for gatifloxacin. Its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free